Dr Reddy's Labs shares in focus as pharma major inks $32 million deal; key details

robot
Abstract generation in progress

Dr Reddy’s Laboratories has acquired the trademarks for Progynova and Cyclo-Progynova in the Indian market from UK-headquartered Mercury Pharma Group Ltd (MPGL) for $32.15 million. This deal marks the pharma major’s entry into the hormone replacement therapy (HRT) segment and aims to strengthen its existing gynaecology portfolio in India. Shares of Dr Reddy’s slipped 0.32 percent on Wednesday, settling at Rs 1280.85 on the BSE.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)